HC Wainwright Reiterates Buy Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $15.00 price objective on the stock.

A number of other brokerages have also recently issued reports on PDSB. Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, PDS Biotechnology presently has a consensus rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Trading Down 5.9%

Shares of PDSB opened at $1.28 on Wednesday. PDS Biotechnology has a 1 year low of $0.51 and a 1 year high of $1.92. The company has a current ratio of 2.98, a quick ratio of 2.98 and a debt-to-equity ratio of 1.27. The stock has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $0.84. The stock has a market cap of $71.45 million, a PE ratio of -1.71 and a beta of 1.20.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Monday, March 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06. On average, sell-side analysts predict that PDS Biotechnology will post -1.2 EPS for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in PDS Biotechnology during the 4th quarter worth approximately $25,000. Tempus Wealth Planning LLC grew its position in PDS Biotechnology by 29.3% during the 4th quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock worth $48,000 after acquiring an additional 14,000 shares during the last quarter. Marshall Wace LLP bought a new stake in PDS Biotechnology during the 2nd quarter worth approximately $91,000. Jane Street Group LLC bought a new stake in PDS Biotechnology during the 2nd quarter worth approximately $92,000. Finally, Susquehanna International Group LLP boosted its position in PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after buying an additional 80,937 shares during the last quarter. 26.84% of the stock is currently owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.